Abstract
Olaparib can be effective in patients with metastatic castration-resistant prostate cancer who have homologous recombination repair gene alterations. In the phase III PROfound trial, the drug extended median radiographic progression-free survival and increased objective response rate in patients with BRCA 1/2 and ATM mutations, compared with enzalutamide or abiraterone plus prednisone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
